1 HEALTH ECONOMICS ARTICLE - BASED IN PPT AND IN THE INITIAL DRAFT. COST-EFFEXTIVENESS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT FOR HER-2 POSITIVE BREAT CANCER.

Instituto Português de Oncologia do Porto Francisco Gentil, EPE adjudicou a Eurotrials, Consultores Cientificos, SA por 9044 €. Ajuste Direto Regime Geral…

Valor
9044 €
Procedimento
Ajuste Direto Regime Geral
Publicação
19 jun. 2019

Read this page in English